Literature DB >> 26321021

Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study.

Gabriella Santangelo1, Carmine Vitale2, Marina Picillo3, Marcello Moccia4, Sofia Cuoco5, Katia Longo6, Domenica Pezzella5, Assunta di Grazia5, Roberto Erro7, Maria Teresa Pellecchia3, Marianna Amboni6, Luigi Trojano8, Paolo Barone9.   

Abstract

INTRODUCTION: In PD, Mild Cognitive Impairment (PD-MCI) occurs since early stages of disease. The aims were to assess presence of PD-MCI in untreated, drug-naive PD patients, and to follow-up the sample over 4 years to ascertain evolution of neurocognitive profile.
METHODS: Seventy-six patients underwent neuropsychological testing at baseline (T0), and after 2 (T1:n = 62) and 4 years (T2:n = 55). Diagnosis of PD-MCI and PD-associated dementia (PDD) was made according to current consensus criteria.
RESULTS: PD-MCI occurred in 25/76 patients (32.9%) at baseline, and 4 of them reverted from PD-MCI to Normal Cognition (Reverters), 7 remained stable (Non-Reverters) and 2 developed PDD at T2; 12 patients were lost to the follow-up. Among the 51 patients with normal cognition (PD-CN) at T0, 27 had normal cognition at T2 (5 of them were Reverters with respect to diagnosis at T1), 5 had MCI at T1 and T2 (Non-Reverters), 9 had MCI at T2 only, whereas 1 developed PDD; 9 patients were lost to the follow-up. At baseline, Reverters (n = 9) had younger age at onset and better performance on constructional visuospatial task than Non-Reverters (n = 12). Compared to patients without PD-MCI at all evaluations (n = 19), Reverters had poorer performance on verbal immediate recall and attention tasks and higher level of apathy at T0. Reduced performance on the Stroop Test at baseline predicted PD-MCI at T2.
CONCLUSION: Executive dysfunctions predicted development of PD-MCI after few years from onset. Reversal from PD-MCI to PD-CN was related to young age at onset and high level of apathy at baseline evaluation.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Apathy; Mild Cognitive Impairment; PD-MCI; Parkinson's Disease–Mild Cognitive Impairment; Parkinson's disease

Mesh:

Year:  2015        PMID: 26321021     DOI: 10.1016/j.parkreldis.2015.08.024

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  42 in total

Review 1.  Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2017-08-14       Impact factor: 3.307

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.

Authors:  Kelly A Mills; Zoltan Mari; Gregory M Pontone; Alexander Pantelyat; Angela Zhang; Nadine Yoritomo; Emma Powers; Jason Brandt; Ted M Dawson; Liana S Rosenthal
Journal:  Parkinsonism Relat Disord       Date:  2016-09-27       Impact factor: 4.891

4.  Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?

Authors:  Angela Federico; Michela Trentin; Giampietro Zanette; Daniela Mapelli; Alessandro Picelli; Nicola Smania; Michele Tinazzi; Stefano Tamburin
Journal:  Neurol Sci       Date:  2017-05-26       Impact factor: 3.307

Review 5.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

6.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

Review 7.  Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments.

Authors:  Costanza Papagno; Luigi Trojano
Journal:  Neurol Sci       Date:  2017-10-17       Impact factor: 3.307

8.  The Parkinson's Disease-Cognitive Rating Scale (PD-CRS): normative values from 268 healthy Italian individuals.

Authors:  Gabriella Santangelo; Giovanna Lagravinese; Valeria Battini; Carlo Chiorri; Mattia Siciliano; Giovanni Abbruzzese; Carmine Vitale; Paolo Barone
Journal:  Neurol Sci       Date:  2017-02-21       Impact factor: 3.307

Review 9.  Initial cognitive changes in Parkinson's disease.

Authors:  Daniel Weintraub; Alexander I Tröster; Connie Marras; Glenn Stebbins
Journal:  Mov Disord       Date:  2018-03-15       Impact factor: 10.338

10.  Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study.

Authors:  Marianna Amboni; Luigi Iuppariello; Alessandro Iavarone; Alfonso Fasano; Raffaele Palladino; Rosaria Rucco; Marina Picillo; Ilaria Lista; Pasquale Varriale; Carmine Vitale; Mario Cesarelli; Giuseppe Sorrentino; Paolo Barone
Journal:  J Neurol       Date:  2018-07-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.